A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

NCT02492763 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Type II Diabetes Mellitus

Interventions

DRUG: MK-8521
DRUG: Placebo
DRUG: Liraglutide
DRUG: Metformin

Sponsor

Merck Sharp & Dohme LLC